New York-based brain-computer interface company Precision Neuroscience Corp. closed $41 million in Series B funding, bringing the company’s total raised to $53 million.
Foorepont Capital Partners led the round with participation from Alumni Ventures, Draper Associates, Mubadala Capital and re.Mind Capital. Existing investors Steadview Capital and B Capital Group also contributed.
Precision will use the funds to grow its team and develop more products. The company plans to undergo FDA regulatory review in the coming months.
“We envision a world where devastating neurological conditions — stroke, brain injury, dementia — are ultimately treatable,” Precision Neuroscience CEO Michael Major said in a statement. “To reach this world, brain–computer interface technology needs to evolve out of the lab and into the clinic. Precision is excited to meet this challenge.”
Atomic AI, a biotech company focused on technology-driven drug discovery, has launched with a $35 million Series A round led by Playground Global, bringing the company’s total raised to $42 million. Is.
Factory HQ, 8VC, Greylock, AME Cloud Ventures, NotBoring and angel investors – including former GitHub CEO Nat Friedman, Curai CEO Neil Khosla Doug Mohr and UC Berkeley professor and cofounder of the Arc Institute Patrick Hsu – also led the round. I attended.
The company aims to create RNA-targeted molecules and RNA-based drugs and tools using machine learning. Models based on RNA structural datasets and large-scale in-house experimental wet-lab biology.
“To create effective and safe small molecules against incurable diseases, there is a critical need to develop tools that accurately predict 3D RNA structures,” AtomicAI founder and CEO Raphael Townshend said in a statement. can do.” “Atom is based on the cutting edge of AI, AI, RNA, and structural biology. We are creating a whole new field of drug discovery.”
San Francisco-based Mighty Health, a lifestyle company that offers exercise, nutrition and daily health programs for people 50 and older, has raised $7.6 million in funding with support from Will Ventures and GFT Ventures. Received support.
AARP also participated in the round with Imad Akhund, CEO of Mercury, a banking company for startups; Basileer Ventures, a strategic arm of VF Corporation; Hyper, an accelerator program; and Z Venture Capital, the messaging app line’s strategic venture arm. Existing investors also participated in the round.
The funding will be used to launch several chronic disease programs and expand strategic partnerships.
“We love that the Mighty Health platform addresses the multiple needs of a polychronic population at the same time as a fundamental lifestyle change, enabling older adults,” said Isaiah Kacyvenski, co-founder and managing partner of Will Ventures. Eliminates the need to use multiple apps and coaches.” Statement
Lithuania-based Oxipit, which offers AI-powered medical imaging tools, secured $4.9 million in funding led by Taiwan Capital, Coinvest Capital and Practica Capital, with participation from angel investors.
The company’s ChestLink application generates reports for patient X-ray studies that show no abnormalities. Oxipit also offers a virtual radiologist assistant called Oxipit Quality, which compares radiology reports and diagnostic images to determine if the report missed anything.
The company will use the funds to further develop its AI-based applications and expand market access in new geographies, with a focus on the UK market.
MedCrypt, a cybersecurity provider for medical device manufacturers, raised its Series B funding round after receiving additional funds from Dexcom Ventures, bringing the company’s total raised to $36.4 million.
The extension comes after the company receives $25 million in Series B funding in November, which brought the company’s total raised to $34.4 million at the time.
Additional funds from the expansion will be used to expand MedCrypt’s engineering team.
#Braincomputer #interface #company #Precision #Neuroscience #raises #41M #digital #health #funding